These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 8730154)
1. Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma. Paira SO J Rheumatol; 1996 Apr; 23(4):792. PubMed ID: 8730154 [No Abstract] [Full Text] [Related]
2. Raynaud's phenomenon as a presenting sign of ovarian adenocarcinoma. Kohli M; Bennett RM J Rheumatol; 1995 Jul; 22(7):1393-4. PubMed ID: 7562782 [TBL] [Abstract][Full Text] [Related]
3. [Adenocarcinoma of the ovary as a study model of cancers and their treatments]. Belpomme D; Filippi MH; Le Bonniec M; Héritier F Bull Cancer; 1993 Feb; 80(2):115-20. PubMed ID: 8173162 [No Abstract] [Full Text] [Related]
4. An atypical presentation of ovarian cancer. Moustafa M; Beynon WB J Obstet Gynaecol; 2002 Jul; 22(4):455-6. PubMed ID: 12521490 [No Abstract] [Full Text] [Related]
5. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management. Grønlund B Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448 [No Abstract] [Full Text] [Related]
6. Bone metastasis as the presenting complaint in ovarian carcinoma. Kingston R; Sparkes J; Leen E; Stafford-Johnson D; Keogh P Acta Obstet Gynecol Scand; 2001 Jul; 80(7):669-70. PubMed ID: 11437731 [No Abstract] [Full Text] [Related]
7. [Therapeutic (im)possibilities in Raynaud's phenomenon]. Smilde TJ; Wollersheim H Ned Tijdschr Geneeskd; 1996 Feb; 140(7):352-7. PubMed ID: 8628419 [No Abstract] [Full Text] [Related]
8. [Analytical studies on the treatment of adenocarcinoma of the ovary]. Matsumoto Y; Kasamatsu T; Sonoda T; Ohmi K; Tsunematsu R; Tanemura K; Yamada T; Kishi K Nihon Gan Chiryo Gakkai Shi; 1984 May; 19(4):778-88. PubMed ID: 6491429 [No Abstract] [Full Text] [Related]
12. Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis. Winkelmann RR; Yiannias JA; DiCaudo DJ; Trotter SC; Farhey Y; Griffing WL; Martorano LM; Winkelmann JC Int J Dermatol; 2016 Jan; 55(1):97-100. PubMed ID: 25266415 [No Abstract] [Full Text] [Related]
13. [Raynaud's phenomenon and finger necrosis after treatment of ovarian seminoma with bleomycin, vinblastine and 5-fluorouracil]. Werquin S; Kacet S; Caron J; Lacroix D; Libersa C; Coget JM; Lekieffre J Ann Cardiol Angeiol (Paris); 1987 Oct; 36(8):409-12. PubMed ID: 2445238 [TBL] [Abstract][Full Text] [Related]
14. Recent advances in the management of women with ovarian cancer. Eltabbakh GH Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412 [TBL] [Abstract][Full Text] [Related]
15. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors]. Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198 [TBL] [Abstract][Full Text] [Related]
16. [Consultation-hospitalization in Raynaud's phenomenon. Case reports]. Metge F Soins Cardiol; 1986 Apr; (38):30-2. PubMed ID: 3637024 [No Abstract] [Full Text] [Related]
17. [Raynaud's phenomenon--current diagnosis and therapy]. Caspary L; Creutzig A Dtsch Med Wochenschr; 2006 May; 131(21):1223-7. PubMed ID: 16721713 [No Abstract] [Full Text] [Related]
18. [Raynaud's phenomenon and Raynaud's disease]. Hansteen V Tidsskr Nor Laegeforen; 1979 Aug; 99(24):1144-5. PubMed ID: 531810 [No Abstract] [Full Text] [Related]